Highlights

  • Cyclopharm reported record H1 FY26 Revenue of approximately A$17.1 million.
  • US Technegas revenue increased approximately 73% YoY to around A$2.1 million.
  • Revenue-generating US sites increased to 70 by July 2026.
  • The company extended its 250 to 300 US site target beyond 31 December 2026.

Cyclopharm (ASX:CYC) is a nuclear medicine company focused on Technegas, a lung ventilation imaging agent used in diagnostic procedures including pulmonary embolism assessment. The company is expanding commercial adoption in the United States following regulatory approval while continuing operations across established international markets.

At the time of writing on 14 August 2026, Cyclopharm (ASX:CYC) was trading at AUD 0.515, down 0.96% on the day.

The company’s latest results highlighted record revenue growth and increasing US adoption, while also reflecting a slower-than-planned rollout timeline.

What Just Happened?

On 2 July 2026, Cyclopharm reported its H1 FY26 results, with global revenue reaching approximately A$17.1 million, representing growth of around 11% YoY.

The United States was the main growth contributor, with Technegas revenue increasing approximately 73% YoY to around A$2.1 million. Revenue-generating US sites increased to 70 by 1 July 2026, compared with 50 at the time of the annual general meeting.

Cyclopharm reported that it had passed peak cash burn as Recurring Revenue expanded and ended the period with approximately A$12.2 million in cash at 30 June 2026.

The company revised its US rollout timeline, stating that its target of 250 to 300 revenue-generating US locations would be achieved after 31 December 2026 rather than by the end of the 2026 calendar year.

Management attributed the slower rollout pace to delays in publication of new international lung imaging clinical guidelines, which had received final approval from relevant nuclear medicine societies but were awaiting publication.

Why It Matters

Cyclopharm’s latest results demonstrate progress in commercialising Technegas in the United States, with higher revenue and increasing numbers of installed sites.

The growth in US revenue is important because each installed site can contribute recurring consumable revenue, creating a foundation for longer-term expansion.

The guideline publication delay remains a key Factor because formal recognition of Technegas within clinical guidance may support broader physician and hospital adoption.

The company’s ability to continue expanding US installations while managing costs will determine whether current revenue growth translates into sustained profitability.

The Bigger Picture

Cyclopharm is an Australian healthcare company focused on Technegas, a technology used for lung ventilation imaging. The product is established across markets including Australia, Europe and Canada, with the United States representing a significant expansion opportunity.

The company received United States Food and Drug Administration approval for Technegas and has been building its commercial presence across US healthcare facilities.

Cyclopharm’s Business model combines an established international revenue base with expansion into the US market. The company has stated a longer-term ambition of exceeding 2,000 US installations, compared with the current installed base.

For investors, the company represents a transition from a niche healthcare technology provider into a broader commercial-stage medical imaging business.

What Could Drive the Shares Next?

The publication of new international lung imaging guidelines remains a key potential catalyst for Cyclopharm. The company has linked adoption timing partly to the availability of these guidelines, which may influence hospital decision-making.

Growth in revenue-generating US sites will also remain important, with investors monitoring progress toward the revised 250 to 300 installation target.

Further evidence of recurring US revenue growth, continued record revenue performance and improved Cash Flow generation will provide additional insight into the commercial progress of Technegas.

Full-year results and future quarterly updates will also help assess whether the company continues moving beyond peak cash burn.

Risks Investors Should Watch

Cyclopharm faces risks associated with US commercial adoption, regulatory processes, competition and product concentration. The rollout of Technegas in the United States may continue to progress slower than expected due to guideline timing, hospital procurement processes or reimbursement factors. The company remains dependent on a single core product, meaning manufacturing, regulatory or Supply issues could have a significant impact. Cyclopharm is also exposed to legal risks, including ongoing competitor-related matters. Additional risks include healthcare market competition, funding requirements, currency movements and Volatility associated with smaller ASX-listed healthcare companies.

Bottom Line

Cyclopharm (ASX:CYC) is progressing the US expansion of Technegas, supported by record H1 FY26 revenue, increasing US installations and higher recurring revenue contribution.

The company has demonstrated commercial progress, particularly in the United States, but the rollout timeline has extended as it awaits publication of supportive clinical guidelines.

The next phase will depend on continued installation growth, adoption of Technegas across US healthcare facilities and the company’s ability to convert expanding revenue into sustainable profitability.